Paul I. Terasaki Foundation

  • Home
  • Purchase Clinical Transplants
  • Publications
  • Contact Us

Clinical Transplants 2012 Table of Contents

Details
Written by Rene Castro
Published on 15 April 2013
Category: Clinical Transplants
  • Print
  • Email
User Rating:  / 1

Available for sale now


Hits: 433
Read more...

Kidney Paired Donation: A single center approach to increase living donor transplantation

Details
Written by Matthew Everly
Published on 24 September 2012
Category: Clinical Transplants
  • Print
  • Email
User Rating:  / 1

 Bingaman A, Kapturczak M, Murphey C, Wright F.

http://www.ncbi.nlm.nih.gov/pubmed/21696052

(Excerpt) "The kidney paired donation KPD program at Methodist Specialty and Transplant Hospital (MSTH) in San Antonio has significantly increased access to transplantation for patients with incompatible living donors, especially for disadvantaged group such as the highly sensitized population of repeat transplant patients and multiparous women. The KPD program increased overall live donor activity allowing MSTH to become the largest living donor kidney transplant center in the nation in 2009. In 2010, MSTH performed 193 living donor kidney transplants with 68 (35%) transplants from the KPD program. This demonstrates that an effective KPD program can significantly benefit difficult patients and increase transplant access and activity in a single center setting."

Full text of this article (click) :

Hits: 440

Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival

Details
Written by Matthew Everly
Published on 24 September 2012
Category: Clinical Transplants
  • Print
  • Email
User Rating:  / 0

 

Author: Matthew Everly, PharmD

http://www.ncbi.nlm.nih.gov/pubmed/21696049

The evidence supporting HLA antibodies as a biomarker in transplant is substantial. It is becoming more clear that these patients represent a new phenotype of patient that is at the highest risk to rapidly progress to chronic damage. Therefore early detection of these high risk patients through serial screening is necessary. Additionally, once patients develop DSA positivity, IgG subclass testing may indicate how eminent his/her graft failure ensue. Moving forward, we should focus monitoring and treating at first detection of persistent antibodies. This may be the only reasonable way to have significant impact on long-term allograft survival.

Click here for full text: 

Hits: 419

Page 1 of 10

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Search

Articles

  • Clinical Transplants

      Clinical Transplants 2012 Table of Contents
      Kidney Paired Donation: A single center approach to increase living donor transplantation
      Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival
      Clinical Management of Renal Transplant Patients with Donor-Specific Alloantibody: The State of the Art
      Impact of Donor-Specific HLA Antibodies (DSA) in Transplant, a Review of the Literature Published In the Last Three Years
      Clinical Transplants 2009: Bortezomib Case Reports in Solid Organ Transplant
      Seminar: Antibody Update 2012: Manuscripts Published in last 12 months
      A Summary of Bortezomib Use in Transplantation Across 29 Centers.
      A "New" Road to Tolerance: Clonal Deletion and Drug Added When Needed (DAWN)
      An Update on Antibody Reduction and Rejection Reversal following Bortezomib Use: A report of 52 cases across 10 centers
      A Review of the Past 25 Years of "Clinical Transplants"
  • Post-Transplant Outcomes

      Seminar: Donor Specific Anti-HLA Antibody (DSA) Monitoring and Removal
      Retrospective Antibody Analysis of Thirty Patients with Kidney Graft Failure
      Retrospective Antibody Analysis of Thirty Patients with Kidney Graft Failure
      Detection of HLA and MICA Antibodies Before Kidney Graft Failure
      Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience
      Donor-Specific HLA Antibodies in Chronic Renal Allograft Rejection: A Prospective Trial with a Four-Year Follow-Up
      High Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies Associated With Chronic Rejection Postliver Transplant
      Natural History of Proteinuria in Renal Transplant Recipients Developing De Novo Human Leukocyte Antigen Antibodies
      A Road to Improving Long-Term Transplant Survival
  • Pre-transplant sensitization

      Outcome of Patients with Preformed Donor-Specific Antibodies Following Alemtuzumab Induction and Tacrolimus Monotherapy
      Preexisting Donor-Specific HLA antibodies Predict Outcome in Kidney Transplantation
      Transplant Glomerulopathy: Risk and Prognosis Related to Anti-Human Leukocyte Antigen Class II Antibody Levels
      Baseline Donor-Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation
      Pretransplant Donor-Specific Antibodies Detected by Single-Antigen Bead Flow Cytometry Are Associated With Inferior Kidney Transplant Outcomes
      Pretransplant Donor-Specific Antibodies in Cytotoxic Negative Crossmatch Kidney Transplants: Are They Relevant?
      Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
      Clinical Relevance of Pretransplant Donor-Specific HLA Antibodies Detected by Single-Antigen Flow-Beads
      Clinical Relevance of Preformed HLA Donor-Specific Antibodies in Kidney Transplantation
feed-image Feed Entries